Medexus Pharmaceuticals (TSE:MDP) has released an update.
Medexus Pharmaceuticals has received FDA approval for their hemophilia B treatment, IXINITY®, for children under 12. This approval, based on positive Phase 3/4 study results, allows the use of IXINITY® for prophylaxis and management of bleeding episodes in pediatric patients, offering hope for improved quality of life for affected children.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.
